US2015072941A1PendingUtilityA1

DPY-30 Binding Peptides

49
Assignee: UNIV MARQUETTEPriority: Aug 8, 2011Filed: Nov 3, 2014Published: Mar 12, 2015
Est. expiryAug 8, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Pinfen YangPriyanka Sivadas
C07K 7/08C07K 14/415C07K 14/405C07K 2319/10A61K 38/00C07K 2319/21C07K 14/47C07K 7/06
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to RSP3 or Ash2L and that bind to Dpy-30.

Claims

exact text as granted — not AI-modified
1 . A peptide of no more than about 50 amino acids, the peptide comprising SEQ ID NO:2, SEQ ID NO:4: or SEQ ID NO:6 or a variant thereof having at least 80% sequence identity to SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, wherein the variant binds to Dpy-30 with a K d  of less than about 100 nM. 
     
     
         2 . The peptide of  claim 1 , wherein the peptide is soluble in water. 
     
     
         3 . The peptide of  claim 1 , wherein the peptide comprises SEQ ID NO:2 and the peptide does not comprise ammo acids 1-280 of SEQ ID NO:1. 
     
     
         4 . The peptide of  claim 1 , wherein the peptide comprises SEQ ID NO:2 and the peptide does not comprise amino acids 319-516 of SEQ ID NO:1. 
     
     
         5 . The peptide of  claim 1 , wherein the peptide consists essentially of SEQ ID NO:2. 
     
     
         6 . The peptide of  claim 1 , wherein the peptide is a fission of SEQ ID NO:2 and a heterologous amino acid sequence. 
     
     
         7 . The peptide of  claim 6 , wherein the heterologous amino acid sequence comprises a protein transduction domain. 
     
     
         8 . The peptide of  claim 1 , wherein the peptide comprises SEQ ID NO:4 and the peptide does not comprise amino acids 1-295 of SEQ ID NO:3. 
     
     
         9 . The peptide of  claim 1 , wherein the peptide comprises SEQ ID NO:4 and the peptide does not comprise amino acids 334-418 of SEQ ID NO:1. 
     
     
         10 . The peptide of  claim 1 , wherein the peptide consists essentially of SEQ ID NO:4. 
     
     
         11 . The peptide of  claim 1 , wherein the peptide is a fusion of SEQ ID NO:4 and a heterologous amino acid sequence. 
     
     
         12 . The peptide of  claim 11 , wherein the heterologous amino acid sequence comprises a protein transduction domain. 
     
     
         13 . The peptide of  claim 1 , wherein the peptide comprises SEQ ID NO:6 and the peptide does not comprise amino acids 1-601 of SEQ ID NO:5. 
     
     
         14 . The peptide of  claim 1 , wherein the peptide consists essentially of SEQ ID NO:6. 
     
     
         15 . The peptide of  claim 1 , wherein the peptide is a fusion of SEQ ID NO:6 and a heterologous amino acid sequence. 
     
     
         16 . The peptide of  claim 15 , wherein the heterologous amino acid sequence comprises a protein transduction domain. 
     
     
         17 .- 25 . (canceled) 
     
     
         26 . A method for inhibiting Dpy-30 binding activity in a cell, the method comprising administering to the cell the peptide of  claim 1  or a peptidomimetic thereof. 
     
     
         27 . A method for inhibiting Dpy-30 binding activity in a cell, the method comprising administering to the cell the peptide of claim  18  or a peptidomimetic thereof. 
     
     
         28 . A pharmaceutical composition comprising: (a) a carrier, and (b) the peptide of  claim 1  or a peptidomimetic thereof. 
     
     
         29 . A pharmaceutical composition comprising: (a) a carrier; and (b) the peptide of claim  18  or a peptidomimetic thereof.

Join the waitlist — get patent alerts

Track US2015072941A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.